Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

The promises and challenges of using gene mutations for patient stratification in follicular lymphoma.

Weigert O, Weinstock DM.

Blood. 2017 Aug 7. pii: blood-2017-07-737353. doi: 10.1182/blood-2017-07-737353. [Epub ahead of print]

PMID:
28784599
2.

Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015.

Gascoyne RD, Nadel B, Pasqualucci L, Fitzgibbon J, Payton JE, Melnick A, Weigert O, Tarte K, Gribben JG, Friedberg JW, Seymour JF, Cavalli F, Zucca E.

Hematol Oncol. 2017 Apr 4. doi: 10.1002/hon.2411. [Epub ahead of print] Review.

PMID:
28378425
3.

It's a long way to the top (if you want to personalize immunotherapy).

Haebe S, Weigert O.

J Immunother Cancer. 2017 Jan 17;5:6. doi: 10.1186/s40425-016-0207-0. eCollection 2017.

4.

HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.

Jacobson C, Kopp N, Layer JV, Redd RA, Tschuri S, Haebe S, van Bodegom D, Bird L, Christie AL, Christodoulou A, Saur A, Tivey T, Zapf S, Bararia D, Zimber-Strobl U, Rodig SJ, Weigert O, Weinstock DM.

Blood. 2016 Nov 24;128(21):2517-2526. Epub 2016 Oct 14.

PMID:
27742706
5.

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.

Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, Rosenwald A, Ott G, Klapper W, Zelenetz AD, Barr PM, Friedberg JW, Ansell S, Sehn LH, Connors JM, Gascoyne RD, Hiddemann W, Unterhalt M, Weinstock DM, Weigert O.

Blood. 2016 Aug 25;128(8):1112-20. doi: 10.1182/blood-2016-05-717355. Epub 2016 Jul 14.

PMID:
27418643
6.

Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones.

Melchardt T, Hufnagl C, Weinstock DM, Kopp N, Neureiter D, Tränkenschuh W, Hackl H, Weiss L, Rinnerthaler G, Hartmann TN, Greil R, Weigert O, Egle A.

Oncotarget. 2016 Aug 9;7(32):51494-51502. doi: 10.18632/oncotarget.9860.

7.

Acetylation of C/EBPα inhibits its granulopoietic function.

Bararia D, Kwok HS, Welner RS, Numata A, Sárosi MB, Yang H, Wee S, Tschuri S, Ray D, Weigert O, Levantini E, Ebralidze AK, Gunaratne J, Tenen DG.

Nat Commun. 2016 Mar 23;7:10968. doi: 10.1038/ncomms10968.

8.

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Möller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O.

Lancet Oncol. 2015 Sep;16(9):1111-22. doi: 10.1016/S1470-2045(15)00169-2. Epub 2015 Aug 6.

PMID:
26256760
9.

Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.

Ferrero S, Pastore A, Scholz CW, Forstpointner R, Pezzutto A, Bergmann L, Trümper L, Finke J, Keller U, Ghione P, Passera R, Hiddemann W, Weigert O, Unterhalt M, Dreyling M.

Leukemia. 2016 Apr;30(4):984-7. doi: 10.1038/leu.2015.215. Epub 2015 Aug 5. No abstract available.

PMID:
26242461
10.

Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.

Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA.

Nat Med. 2015 Jan;21(1):71-5. doi: 10.1038/nm.3751. Epub 2014 Dec 8.

11.

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.

Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM, Weinstock DM.

Blood. 2014 Feb 27;123(9):1293-6. doi: 10.1182/blood-2013-10-531509. Epub 2013 Dec 17.

12.

Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.

Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, Dorfman D, Pinkus G, Weigert O, Hornick JL, Chirieac LR, Hirsch M, Oh DJ, South AP, Leigh IM, Pourreyron C, Cassidy AJ, Deangelo DJ, Weinstock DM, Krop IE, Dillon D, Brock JE, Lazar AJ, Peto M, Cho RJ, Stoeck A, Haines BB, Sathayanrayanan S, Rodig S, Aster JC.

PLoS One. 2013 Jun 18;8(6):e67306. doi: 10.1371/journal.pone.0067306. Print 2013.

13.

CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice.

Weigert O, von Spee C, Undeutsch R, Kloke L, Humrich JY, Riemekasten G.

Arthritis Res Ther. 2013 Feb 27;15(1):R35. doi: 10.1186/ar4188.

14.

Next-generation cDNA screening for oncogene and resistance phenotypes.

Shindoh N, Yoda A, Yoda Y, Sullivan TJ, Weigert O, Lane AA, Kopp N, Bird L, Rodig SJ, Fox EA, Weinstock DM.

PLoS One. 2012;7(11):e49201. doi: 10.1371/journal.pone.0049201. Epub 2012 Nov 7.

15.

Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.

van Bodegom D, Zhong J, Kopp N, Dutta C, Kim MS, Bird L, Weigert O, Tyner J, Pandey A, Yoda A, Weinstock DM.

Blood. 2012 Oct 4;120(14):2853-63. doi: 10.1182/blood-2012-02-413252. Epub 2012 Aug 20.

16.

The evolving contribution of hematopoietic progenitor cells to lymphomagenesis.

Weigert O, Weinstock DM.

Blood. 2012 Sep 27;120(13):2553-61. Epub 2012 Aug 6. Review.

17.

BCL2 suppresses PARP1 function and nonapoptotic cell death.

Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A, Weinstock DM.

Cancer Res. 2012 Aug 15;72(16):4193-203. doi: 10.1158/0008-5472.CAN-11-4204. Epub 2012 Jun 11.

18.

Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.

Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine JA, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH, Weinstock DM.

Cancer Discov. 2012 Jan;2(1):47-55. doi: 10.1158/2159-8290.CD-11-0208. Epub 2011 Dec 12.

19.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.

Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Régnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T, Weinstock DM.

J Exp Med. 2012 Feb 13;209(2):259-73. doi: 10.1084/jem.20111694. Epub 2012 Jan 23.

20.

The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.

Hutter G, Rieken M, Pastore A, Weigert O, Zimmermann Y, Weinkauf M, Hiddemann W, Dreyling M.

Ann Hematol. 2012 Jun;91(6):847-56. doi: 10.1007/s00277-011-1377-y. Epub 2012 Jan 11.

PMID:
22231280

Supplemental Content

Loading ...
Support Center